L. reuteri cells maintained their viability in simulated vaginal fluid as well as the ability to inhibit S. agalactiae
NH 17 growth and to form biofilm. Encapsulated and freeze-dried L. reuteri CRL 1324 can be included in a suitable
pharmaceutical form for vaginal application to prevent or treat urogenital infections in women.